-
Clin Cancer Res: Long-term prognosis of rituximab+lenalidomide→lenalidomide in the treatment of indolent non-Hodgkin’s lymphoma
Time of Update: 2021-09-19
Long-term Follow-up and Correlative Analysis of Two Phase II Trials of Rituximab and Lenalidomide Followed by Continuous Lenalidomide in Untreated and Relapsed/Refractory Indolent Lymphoma .
CCR-20-4622Long-term Follow-up and Correlative Analysis of Two Phase II Trials of Rituximab and Lenalidomide Followed by Continuous Lenalidomide in Untreated and Relapsed / Refractory Indolent Lymphoma in this message
-
J Exp Clin Canc Res: A new breakthrough in cancer immunotherapy-CD112R/CD112 axis
Time of Update: 2021-09-19
(1) Gallbladder cancer(1) Gallbladder cancerKaplan-Meier survival analysis of patients with SC/ASC ( squamous cell/adenosquamous carcinoma) and AC ( adenocarcinoma) showed that high CD112 expression levels are a strong and independent predictor of shorter survival time .
-
NEJM: Study on the effect and safety of iron supplementation intervention for children in iron-deficient areas
Time of Update: 2021-09-19
In Bangladesh, where young children are generally deficient in iron, receiving iron supplement syrup or multi-trace element nutrition powder daily has no significant effect on children's development or other functional outcomes compared with the control .
-
Eur J Cancer: Poor prognosis and high tissue transformation rate of primary refractory follicular lymphoma
Time of Update: 2021-09-19
The 5-year cumulative incidence of tissue transformation of patients in the primary refractory follicular lymphoma group was 34% (95% CI 27-43), while the rate of partial remission (PR) or stable disease (SD) in the treatment group was 34% (95% CI 27-43).
-
This group of Chinese doctors turned the "deadly" poison into a "cure" medicine
Time of Update: 2021-09-19
Since then, Academician Wang Zhenyi of the Shanghai Institute of Hematology pioneered the use of all-trans retinoic acid (ATRA) to treat promyelocytic leukemia and achieved great clinical effects of APL, which can make the complete remission rate of the disease exceed 90%, bringing patients Gave new hope .
-
Nat Med: Efficacy of convalescent plasma infusion for COVID-19 inpatients
Time of Update: 2021-09-19
COVID-19Recently, the top medical journal Nature Medicine published a research article in which researchers conducted an open-label, randomized controlled trial of COVID-19 adults who received oxygen inhalation and recovery plasma treatment within 12 days after the onset of respiratory symptoms ( NCT04348656) .
-
GUT: British Gastroenterology Association Guidelines for the Management of Adult Iron Deficiency Anemia
Time of Update: 2021-09-19
The guidelines also recommend that patients be monitored for Hb response to oral iron in the first 4 weeks and continue treatment for about 3 months after Hb levels have normalized to ensure adequate replenishment of bone marrow iron storage .
-
J Thromb Haemost: The Pregnancy Adaptation Geneva (PAG) Score is used to assess the clinical probability of pulmonary embolism during pregnancy
Time of Update: 2021-09-19
It can be seen that among pregnant women with suspected PE, the PAG score has a high discrimination ability to identify patients with low, medium, or high PTP .
Among pregnant women with suspected PE, the PAG score has a high discrimination ability to identify patients with low, medium, or high PTP .
-
Blood: Long-term efficacy of Venetog+Rituximab in the treatment of recurrent CLL
Time of Update: 2021-09-18
Efficacy of venetoclax plus rituximab for relapsed CLL: 5-year follow-up of continuous or limited- duration therapy .
Efficacy of venetoclax plus rituximab for relapsed CLL : 5-year follow-up of continuous or limited- duration therapy in this message
-
Leukemia: Identification of biomarkers related to endothelial dysfunction and thromboembolism in acute lymphoblastic leukemia
Time of Update: 2021-09-12
The researchers aimed to analyze the three biomarkers (TM, Sdc-1, VEGFR-1) in prospectively collected blood samples and 55 cases and 165 time-matched controls treated under the NOPHO ALL 2008 regimen for thromboembolism The correlation between risks .
-
JCEM: Decreased monocyte count is associated with gestational diabetes, macrosomia and inflammation
Time of Update: 2021-09-12
In addition, the cohort study showed that with the decrease of monocyte count in the first trimester, the incidence of GDM and macrosomia, blood sugar level and newborn weight increased stepwise .
-
Clin Cancer Res: Long-term follow-up results of Venetog monotherapy for relapsed/refractory non-Hodgkin's lymphoma
Time of Update: 2021-09-12
In the phase 1 clinical trial of NHL, the overall objective response rate (ORR) was as high as 44%This article reports the long-term follow-up results of the above four cohorts .
Long-term Follow-up of Patients with Relapsed or Refractory Non--Hodgkin Lymphoma Treated with Venetoclax in a Phase I, First-in-Human Study .
-
EClinicalMed: A new genetic mutation site related to the outcome of hematopoietic stem cell transplantation in patients with hematological malignancies!
Time of Update: 2021-09-11
2887 GWAS patients with acute myeloid leukemia (AML), myelodysplastic syndrome (MDS) and acute lymphoblastic leukemia (ALL)Variants associated with overall survivalVariants associated with overall survivalThrough the meta-analysis of the two cohorts, multiple non-HLA locus variants were found in the whole genome and are closely related to the clinical outcome of patients after transplantation: overall survival (OS) and the rs9990017 locus variation on the MBNL1 gene of the recipient and LINC02774 gene rs10927108 donor site - receptor gene Related mismatches (risk 1.
-
J Clin Oncol: The efficacy and safety of new second-generation CD19-CAR T cells in the treatment of adult patients with relapsed/refractory B-ALL
Time of Update: 2021-09-11
7)In summary, among r/r adult B-ALL patients, AUTO1 showed tolerable safety, high remission rate and excellent duration .
In r/r adult B-ALL patients, AUTO1 showed tolerable safety, high remission rate and excellent duration.
-
Eur J Cancer: Efficacy and safety of Sepalizumab (GLS-010) in the treatment of Chinese patients with relapsed or refractory classic Hodgkin's lymphoma
Time of Update: 2021-09-11
Efficacy and safety of GLS-010 (zimberelimab) in patients with relapsed or refractory classical Hodgkin lymphoma: A multicenter, single-arm, phase II study .
021Efficacy and safety of GLS-010 ( zimberelimab) in patients with relapsed or refractory classical Hodgkin lymphoma: A multicenter, single-arm, phase II study in this message
-
Is it necessary to carry out antibody testing for people who have been vaccinated?
Time of Update: 2021-09-11
To stimulate the activation of the immune system produced by the human body , neutralizing antibodies are not the only immunityZheng Zhongwei said that the results of clinical trials have shown that the new coronavirus vaccine has strong immunogenicity .
-
J Clin Oncol: Ibrutinib treatment can significantly increase the risk of atrial fibrillation, bleeding and heart failure in CLL patients
Time of Update: 2021-09-11
Cumulative incidence of heart failure in the two groups for 1-3 yearsCumulative incidence of heart failure in the two groups for 1-3 yearsIn summary, ibrutinib is associated with an increased risk of AF, bleeding, and HF in patients with chronic lymphocytic leukemia , but has nothing to do with the risk of AMI or stroke .
-
Clin Cancer Res: Efficacy and safety of domestic BTK inhibitor Zebutinib in the treatment of refractory/relapsed Waldenström macroglobulinemia
Time of Update: 2021-09-11
Zebutinib (Zanubrutinib) is a powerful BTK inhibitor lymphoma independently developed by BeiGene in ChinaThis is a single-arm, multi-center phase II study that recruited R/R WM patients who had received at least one treatment regimen in the past and received oral zebutinib (160 mg, 2/day) daily until Progression of the disease or intolerable toxicity .
-
Circulation: Effect of Vericiguat on hemoglobin and clinical outcome of patients with heart failure with reduced ejection fraction
Time of Update: 2021-09-11
Recently, the heart blood vessels published a research article in the authoritative magazine on the field of Circulation, the researchers aimed to investigate Vericiguat, randomized hemoglobin, the association between anemia, as well as the benefits of Vericiguat whether related to baseline hemoglobin .
-
J Hematol Oncol: Adverse events in the treatment of oral azacitidine in patients with AML in remission
Time of Update: 2021-09-11
In the QUAZAR AML-001 trial, compared with placebo, oral azacitidine maintenance treatment can prolong the overall survival of AML patients who achieved first remission after IC treatment but without indications for transplantation by 9.
